Publication | Open Access
Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma
56
Citations
42
References
2022
Year
Upfront targeted therapy for patients with BRAF-mutant pHGG is feasible and effective, with superior clinical outcomes compared to historical data. This promising treatment paradigm is currently being evaluated prospectively in the Children's Oncology Group ACNS1723 clinical trial.
| Year | Citations | |
|---|---|---|
Page 1
Page 1